Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:GANX
DateTimeSourceHeadlineSymbolCompany
05/30/20246:00AMGlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024NASDAQ:GANXGain Therapeutics Inc
05/14/20243:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GANXGain Therapeutics Inc
05/14/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
05/14/20246:30AMGlobeNewswire Inc.Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
04/24/20248:25AMGlobeNewswire Inc.Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
04/08/20248:25AMGlobeNewswire Inc.Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerNASDAQ:GANXGain Therapeutics Inc
04/01/20248:25AMGlobeNewswire Inc.Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerNASDAQ:GANXGain Therapeutics Inc
03/26/20247:00AMGlobeNewswire Inc.Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
03/15/20241:30PMGlobeNewswire Inc.Gain Therapeutics to Present at Public Ventures Discovery DayNASDAQ:GANXGain Therapeutics Inc
03/05/20247:00AMGlobeNewswire Inc.Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/27/20241:00PMGlobeNewswire Inc.Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/22/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
02/14/202411:29AMGlobeNewswire Inc.Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightNASDAQ:GANXGain Therapeutics Inc
02/06/20248:56AMGlobeNewswire Inc.UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
02/06/20247:00AMGlobeNewswire Inc.Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
01/31/20244:26PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
01/31/20247:00AMGlobeNewswire Inc.Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateNASDAQ:GANXGain Therapeutics Inc
01/02/20243:09PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GANXGain Therapeutics Inc
01/02/20247:00AMGlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024NASDAQ:GANXGain Therapeutics Inc
01/01/202411:15PMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GANXGain Therapeutics Inc
12/19/20233:52PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GANXGain Therapeutics Inc
12/01/20237:00AMGlobeNewswire Inc.Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelNASDAQ:GANXGain Therapeutics Inc
11/29/20237:00AMGlobeNewswire Inc.Gain Therapeutics to Participate in AI Driven Drug Discovery SummitNASDAQ:GANXGain Therapeutics Inc
11/24/202312:01PMGlobeNewswire Inc.Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment OptionNASDAQ:GANXGain Therapeutics Inc
11/24/20235:07AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
11/22/20234:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
11/21/20237:54AMGlobeNewswire Inc.Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and WarrantsNASDAQ:GANXGain Therapeutics Inc
11/20/20233:22PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
11/20/20233:03PMGlobeNewswire Inc.Gain Therapeutics Announces Proposed Public OfferingNASDAQ:GANXGain Therapeutics Inc
11/17/20233:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GANX

Your Recent History

Delayed Upgrade Clock